We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Try the New Site
We're building a modernized ClinicalTrials.gov! Visit Beta.ClinicalTrials.gov to try the new functionality.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Autologous Stem Cell Transplantation for Refractory Systemic Lupus Erythematosus (ASSIST) (ASSIST)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT00750971
Recruitment Status : Unknown
Verified March 2017 by Falk Hiepe, Charite University, Berlin, Germany.
Recruitment status was:  Recruiting
First Posted : September 11, 2008
Last Update Posted : March 20, 2017
Sponsor:
Information provided by (Responsible Party):
Falk Hiepe, Charite University, Berlin, Germany

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
While glucocorticoids and immunosuppressants ameliorate manifestations of SLE in many patients, current therapies are insufficient to control the disease in a subset of patients, and their clinical prognosis remains poor due to the development of vital organ failure, cumulative drug toxicity and to the increased risk of cardiovascular disease and malignancy. Immunoablative chemotherapy followed by autologous hematopoietic stem cell transplantation (ASCT) has recently emerged as a promising experimental therapy for severely affected patients, providing them the potential to achieve treatment-free, long-term remission. The investigators postulate that immunoablative therapy eliminates or effectively reduces the level of autoreactive T and B lymphocytes and then regeneration of de novo immunity resets the autoreactive immune system into a self-tolerant, protective immune system resulting in prolonged and treatment-free remission.

Condition or disease Intervention/treatment Phase
Systemic Lupus Erythematosus Procedure: Immunoablation and Autologous Hematopoietic Stem Cell Transplantation Phase 2

Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 30 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open-Label, Phase II Multicenter Cohort Study of Immunoablation With Cyclophosphamide and Antithymocyte-Globulin and Transplantation of Autologous Cd34-Enriched Hemapoietic Stem Cells Versus Currently Available Immunosuppressive/Immunomodulatory Therapy for Treatment of Refractory Systemic Lupus Erythematosus
Study Start Date : August 2008
Estimated Primary Completion Date : July 2020
Estimated Study Completion Date : August 2020

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Lupus

Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: 1
Immunoablation and Autologous Hematopoietic Stem Cell Transplantation
 Procedure: Immunoablation and Autologous Hematopoietic Stem Cell Transplantation
Transplantation of purified CD34+ autologous hematopoietic stem cells mobilized with cyclophosphamide (200mg/m2)and G-CSF (10µg/kg/d) after immunoablation with cyclophosphamide (200mg/kg)and rabbit-antithymocyteglobulin (90mg/kg)
Active Comparator: 2
Best currently available immunosuppressive/immunomodulatory therapy
 Procedure: Immunoablation and Autologous Hematopoietic Stem Cell Transplantation
Transplantation of purified CD34+ autologous hematopoietic stem cells mobilized with cyclophosphamide (200mg/m2)and G-CSF (10µg/kg/d) after immunoablation with cyclophosphamide (200mg/kg)and rabbit-antithymocyteglobulin (90mg/kg)


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. SLEDAI [ Time Frame: 48 months ]

Secondary Outcome Measures :
  1. Serologic response (autoantibodies) [ Time Frame: 48 months ]
  2. Immune Reconstitution [ Time Frame: 48 months ]
  3. Organ-specific response parameters [ Time Frame: 48 months ]

Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 60 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Diagnosis of SLE according to American College of Rheumatology (ACR) classification criteria
  2. Age between 18 and 60 years, inclusive
  3. Provision of informed consent

  4. Active disease, refractory to standard immunosuppressive therapy defined as:

    • BILAG level A and a SLEDAI-score of at least 10, despite treatment with high-dose corticosteroids and pulse intravenous CYC at doses of 500-1000mg/m2 for at least 6 months or mycophenolate mofetil (MMF) at doses of at least 2g -
    • Lupus nephritis with renal biopsy performed within one year prior to screening showing glomerulonephritis WHO class III or IV
    • Parenchymal disease of heart or lung
    • Neuropsychiatric lupus
    • Autoimmune cytopenia OR
    • recurrence of disease activity (defined as BILAG level A and a SLEDAI of at least 10) within one year after successful induction therapy with cyclophosphamide or MMF in the presence of an adequate maintenance therapy with either cyclophosphamide (at least 500mg/m2 monthly), mycophenolate mofetil (at least 2g daily), azathioprine (at least 1.5mg/kg/d), methotrexate (at least 15mg weekly), cyclosporine (at least 3mg/kg/d) in patients with persistent anti-dsDNA antibodies

Exclusion Criteria:

  1. Severe concomitant disease or organ damage

    • renal: renal insufficiency with glomerular filtration rate below 40ml/min
    • cardiac: congestive heart failure, LVEF < 40% determined by echocardiogram, uncontrolled arrhythmia
    • pulmonary: mean pulmonary arterial pressure >50mmHg, DLCO < 40 % predicted
    • gastrointestinal: liver cirrhosis; SGOT, SGPT greater than 2 x the upper limit of normal, unless due to active lupus
  2. Ongoing cancer or history of malignancy within 5 years of screening
  3. Women who are pregnant or breastfeeding or use non-reliable methods of contraception
  4. Subjects with active systemic infection
  5. Subjects with history of active viral infection within 6 months prior to screening, known HIV-infection or chronic Hepatitis B or Hepatitis C
  6. History of allergic reaction to cyclophosphamide, G-CSF or ATG
  7. Use of immunosuppressive agents for indications other than SLE
  8. Any comorbidity that in the opinion of the investigator would jeopardize the ability of the subject to tolerate therapy
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00750971


Contacts
Layout table for location contacts
Contact: Falk Hiepe, Prof. +49 30 450 513026 falk.hiepe@charite.de
Contact: Renate Arnold, Prof. +49 30 450-553-302 renate.arnold@charite.de

Locations
Layout table for location information
Germany
Universitätsmedizin Charité Recruiting
Berlin, Germany, 10117
Contact: Falk Hiepe, Prof    +49 30 450 513026      
Principal Investigator: Falk Hiepe, Prof.         
Universitätsklinik Düsseldorf Recruiting
Düsseldorf, Germany, 40225
Contact: Mathias Schneider, Prof.    +49 (0) 211-8117817      
Principal Investigator: Mathias Schneider, Prof.         
Universitätsklinikum Essen Recruiting
Essen, Germany, 45239 Essen
Contact: Christoph Specker, Prof.    +49 (0)201-84081214      
Principal Investigator: Christoph Specker, Prof.         
Universitätsklinik Heidelberg Recruiting
Heidelberg, Germany, 69120
Contact: Hanns-Marting Lorenz, Prof.    +49 (0) 6221-568044      
Principal Investigator: Hanns-Martin Lorenz, Prof.         
Universitätsklinik Köln Recruiting
Köln, Germany, 50937
Contact: Andrea Rubbert-Roth, PD    +49 (0) 221-4783993      
Principal Investigator: Andrea Rubbert-Roth, PD         
Universitäsklinik Mainz Recruiting
Mainz, Germany, 55101
Contact: Karin Kolbe, MD         
Principal Investigator: Karin Kolbe, MD         
Universitätsklinik Tübingen Recruiting
Tübingen, Germany, 72026
Contact: Ina Kötter, PD    +49 (0) 7071-2984095      
Principal Investigator: Ina Kötter, PD         
Universitätsklinik Würzburg Recruiting
Würzburg, Germany, 97070
Contact: Hans-Peter Tony, Prof.    +49 (0) 931-20170420      
Principal Investigator: Hans-Peter Tony, Prof.         
Sponsors and Collaborators
Charite University, Berlin, Germany
Investigators
Layout table for investigator information
Principal Investigator: Falk Hiepe, Prof Universitätsmedizin Charité
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Publications:

Layout table for additonal information
Responsible Party: Falk Hiepe, Prof. Dr. Falk Hiepe, Charite University, Berlin, Germany
ClinicalTrials.gov Identifier: NCT00750971    
Other Study ID Numbers: CT-1306
First Posted: September 11, 2008    Key Record Dates
Last Update Posted: March 20, 2017
Last Verified: March 2017
Keywords provided by Falk Hiepe, Charite University, Berlin, Germany:
ASSIST
SLE
Stem Cell Transplantation
Tolerance
Additional relevant MeSH terms:
Layout table for MeSH terms
Lupus Erythematosus, Systemic
Connective Tissue Diseases
Autoimmune Diseases
Immune System Diseases